ZA202210633B - Methods for dose initiation of aripiprazole treatments - Google Patents

Methods for dose initiation of aripiprazole treatments

Info

Publication number
ZA202210633B
ZA202210633B ZA2022/10633A ZA202210633A ZA202210633B ZA 202210633 B ZA202210633 B ZA 202210633B ZA 2022/10633 A ZA2022/10633 A ZA 2022/10633A ZA 202210633 A ZA202210633 A ZA 202210633A ZA 202210633 B ZA202210633 B ZA 202210633B
Authority
ZA
South Africa
Prior art keywords
aripiprazole
treatments
methods
dose initiation
dose
Prior art date
Application number
ZA2022/10633A
Other languages
English (en)
Inventor
Harlin Matthew
Wang Xiaofeng
Wang Yanlin
Raoufinia Arash
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75581573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA202210633(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of ZA202210633B publication Critical patent/ZA202210633B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
ZA2022/10633A 2020-04-01 2022-09-26 Methods for dose initiation of aripiprazole treatments ZA202210633B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003544P 2020-04-01 2020-04-01
PCT/JP2021/014194 WO2021201239A1 (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments

Publications (1)

Publication Number Publication Date
ZA202210633B true ZA202210633B (en) 2025-01-29

Family

ID=75581573

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/10633A ZA202210633B (en) 2020-04-01 2022-09-26 Methods for dose initiation of aripiprazole treatments

Country Status (16)

Country Link
US (6) US20230129919A1 (cg-RX-API-DMAC7.html)
EP (3) EP3941470A1 (cg-RX-API-DMAC7.html)
JP (4) JP7584535B2 (cg-RX-API-DMAC7.html)
KR (3) KR20240165486A (cg-RX-API-DMAC7.html)
CN (3) CN115397420A (cg-RX-API-DMAC7.html)
AU (2) AU2021248212A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022018721A2 (cg-RX-API-DMAC7.html)
CA (3) CA3163321C (cg-RX-API-DMAC7.html)
ES (1) ES2995466T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241574T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069157T2 (cg-RX-API-DMAC7.html)
MX (2) MX2022012354A (cg-RX-API-DMAC7.html)
PL (1) PL4125903T3 (cg-RX-API-DMAC7.html)
TW (4) TWI865760B (cg-RX-API-DMAC7.html)
WO (2) WO2021201238A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202210633B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US20230129919A1 (en) 2020-04-01 2023-04-27 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
WO2024194955A1 (en) 2023-03-17 2024-09-26 Otsuka Pharmaceutical Co., Ltd. Methods of dispersing aripiprazole injectable preparations
CN120957722A (zh) 2023-04-26 2025-11-14 大塚制药株式会社 用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
KR101892745B1 (ko) 2007-06-25 2018-08-28 오쓰까 세이야꾸 가부시키가이샤 코어/셀 구조를 가진 미소구
CA2655335C (en) 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US10525057B2 (en) * 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
KR20200010320A (ko) 2017-05-16 2020-01-30 보우 리버 엘엘씨 치료 방법
AU2019230014B2 (en) * 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
US20230129919A1 (en) 2020-04-01 2023-04-27 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments

Also Published As

Publication number Publication date
BR112022018721A2 (pt) 2022-11-01
MX2022012353A (es) 2022-10-31
HUE069157T2 (hu) 2025-02-28
US20230129919A1 (en) 2023-04-27
KR20220161403A (ko) 2022-12-06
TWI906279B (zh) 2025-12-01
TW202200142A (zh) 2022-01-01
KR20240165486A (ko) 2024-11-22
AU2021248212A1 (en) 2022-12-01
CA3136727A1 (en) 2021-10-07
EP3941470A1 (en) 2022-01-26
MX2022012354A (es) 2022-10-31
EP4125903A1 (en) 2023-02-08
TWI865760B (zh) 2024-12-11
JP7584535B2 (ja) 2024-11-15
ES2995466T3 (en) 2025-02-10
US12691056B2 (en) 2026-07-28
WO2021201239A1 (en) 2021-10-07
CN119792290A (zh) 2025-04-11
US20240374506A1 (en) 2024-11-14
JP7891516B2 (ja) 2026-07-16
EP4125903B1 (en) 2024-10-09
JP2023520004A (ja) 2023-05-15
KR102732030B1 (ko) 2024-11-20
EP4467194A3 (en) 2025-01-08
AU2021245713A1 (en) 2022-12-01
PL4125903T3 (pl) 2025-02-03
JP2025176037A (ja) 2025-12-03
CA3163321A1 (en) 2021-10-07
JP7733000B2 (ja) 2025-09-02
US20220160621A1 (en) 2022-05-26
US20230225962A1 (en) 2023-07-20
TW202523329A (zh) 2025-06-16
EP4125903C0 (en) 2024-10-09
KR20220161402A (ko) 2022-12-06
TW202200141A (zh) 2022-01-01
WO2021201238A1 (en) 2021-10-07
BR112022018647A2 (pt) 2022-11-08
JP2023519425A (ja) 2023-05-10
CN115397420A (zh) 2022-11-25
US20260034053A1 (en) 2026-02-05
EP4467194A2 (en) 2024-11-27
CN115379842A (zh) 2022-11-22
CA3163321C (en) 2023-12-19
CA3212191A1 (en) 2021-10-07
HRP20241574T1 (hr) 2025-01-31
US20260115131A1 (en) 2026-04-30
JP2025020306A (ja) 2025-02-12
TW202615022A (zh) 2026-04-16

Similar Documents

Publication Publication Date Title
EP4467194A3 (en) Methods for dose initiation of aripiprazole treatments
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
EP4647125A3 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
NZ602675A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
JP2018526460A5 (cg-RX-API-DMAC7.html)
AR120399A1 (es) Un método de tratamiento de un cáncer positivo para dll3
MX2025005134A (es) Regimen de dosificacion intermitente de azenosertib en el tratamiento del cancer
IL173346A0 (en) Treatment of dependence withdrawal
WO2022010813A3 (en) Enhancing immune responses through targeted antigen expression
MX2022013391A (es) Pauta posologica para el tratamiento del cancer.
JP2023520004A5 (cg-RX-API-DMAC7.html)
MX2026000276A (es) Composiciones y metodos para tratar la esclerosis multiple
Engelsman et al. Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an EORTC study.
CN109172550B (zh) 一种复合麻醉药物
MX2023005695A (es) Administracion de agonista de sting, inhibidores de puntos de control y radiacion.
JP2022520859A5 (cg-RX-API-DMAC7.html)
MX2025012679A (es) Inicio de dosis para el tratamiento de la esquizofrenia o el trastorno bipolar i con aripiprazol
Cho et al. Anaphylaxis induced by priming dose of rocuronium during induction of anesthesia: Report of two cases
NZ781127B2 (en) Mirikizumab for use in a method of treating crohn's disease
MX2023011047A (es) Dc009 para el tratamiento de accidente cerebro-vascular isquemico agudo.
MX2026001833A (es) Compuesto azd5462 para usar en el tratamiento de insuficiencia cardiaca
MX2026001798A (es) Metodo para tratar o prevenir enfermedades relacionadas con el colesterol utilizando un inhibidor de pcsk9
NZ765616A (en) Esketamine for the treatment of depression
MX2024008256A (es) Metodos de tratamiento de la enfermedad por coronavirus y compuestos para el mismo.
NZ773583A (en) Methods of treating psoriasis